Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03716739 · ClinicalTrials.gov registry record · Phase 2
Improving Quality of Life of Prostate Cancer Survivors With Androgen Deficiency
A Phase 2 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 136
- Enrollment target
NCT03716739 is a Phase 2 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 136 participants.
The verdict
NCT03716739, a Phase 2 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 136 participants
- Enrollment target
Study Summary
The purpose of this phase II trial is to determine the efficacy and safety of testosterone replacement therapy (TRT) in improving the symptoms of androgen deficiency and health-related quality of life in men with prostate cancer who have undergone radical prostatectomy.
Interventions
- DRUG Placebo
- DRUG Testosterone Cypionate 100 MG/ML
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 136 participants |
| Start Date | 2019-03-19 |
| Est. Completion | 2025-07-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03716739
The ClinicalTrials.gov registry entry for NCT03716739 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 136 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03716739 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03716739 about?
NCT03716739 is a clinical study titled "Improving Quality of Life of Prostate Cancer Survivors With Androgen Deficiency". The purpose of this phase II trial is to determine the efficacy and safety of testosterone replacement therapy (TRT) in improving the symptoms of androgen deficiency and health-related quality of life in men with prostate cancer who have undergone radical prostatectomy.
What is the current status of trial NCT03716739?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 136 participants. The study started on 2019-03-19. Estimated completion is 2025-07-16.
What interventions are being tested in trial NCT03716739?
The interventions under investigation include: Placebo (DRUG), Testosterone Cypionate 100 MG/ML (DRUG).
Who is sponsoring clinical trial NCT03716739?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.